Work

A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.10044

Authors: Mehmet Fevzi Ozkaynak, Andrew Lee Gilman, Alice L. Yu, Wendy B. London, Paul M Sondel, Malcolm A. Smith, Robert Seeger, C. Patrick Reynolds, John M. Maris, Julie R. Park

Institutions: New York Medical College, Carolinas Medical Center, Rady Children's Hospital-San Diego, Boston Children's Hospital, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, University of Wisconsin–Madison, Children's Hospital of Los Angeles, Texas Tech University Health Sciences Center, Children's Hospital of Philadelphia, Seattle Children's Hospital

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602517698

Cites:

Cited by: 14

Related to: 10